Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.37 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15485807 | 0.91 | ALDH1A1 (0.47) | CNR2TYRALDH1A1CNR1LMNA | |
| SCHEMBL843837 | 0.82 | CNR2 (0.60) | CNR2TYRALDH1A1CNR1KMT2A | |
| SCHEMBL859046 | 0.77 | CNR2 (0.78) | CNR2CNR1LMNA | |
| SCHEMBL11557176 | 0.77 | ALDH1A1 (0.53) | CNR2TYRALDH1A1HTTLMNA | |
| SCHEMBL859045 | 0.76 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL844142 | 0.75 | ALDH1A1 (0.46) | CNR2TYRALDH1A1LMNAPOLB | |
| SCHEMBL25062490 | 0.72 | NOTUM (0.51) | ALDH1A1HTTLMNAKMT2AKDM4E | |
| SCHEMBL11555438 | 0.72 | ALDH1A1 (0.48) | CNR2TYRALDH1A1LMNAPOLB | |
| SCHEMBL15485636 | 0.71 | LMNA (0.46) | ALDH1A1LMNAPOLBRECQLCYP2B6 | |
| SCHEMBL15486289 | 0.71 | LMNA (0.46) | ALDH1A1LMNAPOLBRECQLCYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2012-06-14 | — | — | US | disclosed |
| EP-2432763-A1 | 1,4 DIHYDROPYRIDINE DERIVATIVES AND THEIR USES | Université de Lille 2 Droit et Santé (FR) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133973-A1 | 1,4 DIHYDROPYRIDINE DERIVATIVES AND THEIR USES | UNIVERSITE LILLE 2 DROIT ET SANTE (FR) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CNR2, CNR1, TRPV1 | CNR2 1/4885TYR 2630/4885ALDH1A1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.